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ABSTRACT 
 
Background: Epistaxis is a common condition that can be associated with significant morbidity and places a 
considerable burden on our healthcare system.  This national audit of management seeks to assess current 
practice against newly created consensus recommendations and expand our current evidence base. 
 
Method: Patients that met inclusion criteria at 113 registered sites across the UK, had their management 
compared with audit standards during a 30-day window.  Data was further utilised for explorative analysis. 
 
Results:  1826 cases were uploaded to the database, representing 94% of all cases that met the inclusion 
criteria at participating sites. 62% of patients were successfully treated by ENT clinicians within 24 hours 
and the 30-day recurrent presentation rate across the dataset was 13.9%.  Significant event analysis 
revealed an all-cause 30-day mortality rate of 3.4%. 
 
Conclusion: Audit findings demonstrate a varying alignment with consensus guidance with explorative 
analysis countering some previously well-established tenets of management. 
 
INTRODUCTION 
 
The Care Quality Commission highlights ‘Good Governance’ as a fundamental standard of care.  Central to 
this, clinical audit seeks to assess the quality and safety of this care.  Whilst local audit is well established in 
otorhinolaryngology, there has been a paucity of national centrally-delivered audit within our specialty 
since the National Prospective Tonsillectomy Audit(1) and the National Audit of Sino-nasal Surgery(2) 
published in 2005 and 2006 respectively.  ENT-UK and the British Rhinological Society (BRS) sought to 
address this deficiency by challenging INTEGRATE (the National ENT Trainee Research Network) to design 
and deliver a national audit of management for the hospital treatment of epistaxis.   
 
Epistaxis is the most common acute disorder managed by ENT services in the UK, with around 25,000 acute 
presentations to NHS hospitals each year (http://www.hscic. gov.uk/ accessed 11/07/17) . Despite this high 
incidence, prior to this initiative there were no nationally accepted guidelines for its management.  A pilot 
audit(3) led by INTEGRATE has confirmed significant variation in existing treatment between hospital trusts.  
 
This audit aims to compare current management against agreed consensus management guidelines(4), 
identify variation in practice and perform exploratory analysis of the dataset to expand our current 
understanding of this common condition.  As a result of this audit, we seek to generate a program of 
change to deliver improved and standardised evidence-based hospital care of epistaxis across the UK.  
 
 
METHOD 
 
Organisation and design:  This audit was designed and delivered by INTEGRATE following the creation of a 
project steering committee comprising of 6 trainees and 2 consultant executive members. One trainee was 
nominated to chair the steering committee and co-ordinate the audit. 
 
Audit standards: Following a comprehensive and systematic review of the literature(5-9), national consensus 
recommendations for the hospital management of epistaxis were developed(4).  These recommendations 
were utilised to generate a draft data-collection tool (DCT) for the audit including 30-day outcome data.  
The draft DCT was adapted in line with lessons learnt from a multi-centre pilot audit(3) before undergoing 
multi-level scrutiny, initially by the audit steering committee and subsequently by the ENT-UK executive 
committee.  The agreed DCT was then optimised by commissioned statisticians at the Peninsula Clinical 
Trials Unit (PenCTU) for ease of subsequent analysis following data collection. 
  
Audit period: A 30-day data audit window was identified from midnight on the 7th of November 2016. 
 
Inclusion/Exclusion: During the audit window, patients ≥16yrs old presenting emergently, as an 
unscheduled event with a diagnosis of epistaxis that were subsequently managed by ENT services were 
included in the audit.  This included patients referred from the Emergency Department (ED), primary care 
or from other specialties within participating units.  Patients attending pre-arranged appointments for the 
management of chronic self-limiting epistaxis were excluded, as well as patients seen and treated by 
Emergency Department staff without referral to ENT services.  Telephone encounters were not included. 
 
Collaborator Engagement: Site-leads were recruited from ENT departments throughout the UK via a 
network of regional trainee representatives, engagement with the Specialist Advisory Committee and 
through open advertisement via the Association of Otolaryngologists in Training.  Site-leads were given on-
line supporting material to aid in the local delivery of the audit and were invited to attend a launch event 
prior to the audit window to further clarify the audit process. Throughout local preparation, site-leads 
were requested to complete an on-line task list detailing their progress to allow the steering committee to 
maintain a strategic overview of the project. 
 
Data collection: Cases meeting the inclusion and exclusion criteria were identified prospectively at the 
point of presentation.  Throughout the audit window, ED and ENT practitioners were encouraged to make 
detailed clinical notes following all epistaxis related clinical encounters in line with good medical 
practice(10) guidance.  Audit proformas were not utilised by treating clinicians to prospectively record 
clinical information due to concerns regarding their impact on pre-existing standard practice.  At the point 
of discharge audit data was gathered by collaborators from hospital notes, uploaded via a web-based 
portal and stored in the Data Safe Haven on a secure server hosted at University College London. The 
server was certificated to the ISO27001 information security standard and conforms to the NHS 
Information Governance Toolkit. All connections to the Data Safe Haven server via the web portal were 
secured with 256-bit SHA encryption.   
 
Following closure of the 30-day window a clinical coding search was conducted in all participating units to 
highlight all epistaxis presentations during the audit period to established whether any cases had been 
missed.  All cases were examined against inclusion/exclusion criteria and then cross referenced with the 
cases uploaded to the database.  Where cases were missed, hospital notes were requested and if possible, 
added retrospectively to the database.  Any cases identified retrospectively were highlighted as such for 
the purposes of data analysis. 30-day outcome data was gathered for all uploaded cases via note retrieval 
through local audit departments.  Units were also asked to provide trust quoted population at risk data. No 
identifiable patient data was uploaded to the server, all submissions were anonymised using an audit 
specific key for each patient devised and stored locally at each site in line with the clinical governance 
policy at each site.  
 
Management of data submission and quality: The audit steering committee utilised a dedicated online 
platform (https://www.entintegrate.org) to facilitate communication between collaborators, to rapidly 
respond to potential problems and to support timely and high-quality data submission. On completion of 
data submission, steering committee members inspected submitted data for errors, duplication or 
omissions.  Where necessary, site-leads were contacted to remedy identified discrepancies. 
 
Audit and ethical approval: Prior to data collection, an audit proposal was submitted for approval to the 
audit departments of all participating units, in line with local policy. Caldicott Guardians were contacted at 
all sites and approval sought for the method of data collection.  Although formal patient consent was 
neither sought nor required, patient information regarding the audit was displayed at all participating sites 
and individuals invited to be excluded from the audit if they desired. Many evidence gaps were identified 
during the consensus recommendations process for epistaxis management(ref).  Therefore, we sought NHS 
Research Ethics Committee (NREC) guidance regarding the use of the dataset beyond comparison against 
identified audit standards.  Completion of the Health Research Authority Guidance Tool confirmed formal 
NREC approval was not required for this purpose. 
 
Statistical Analysis Strategy: When presenting our analysis, we define length of stay (LOS) as the time from 
hospital presentation to discharge, which reflects the entire treatment process. We define time to ENT as 
the time from presentation through to first ENT review. Haemostasis time (HT) is the time from first ENT 
review to when final haemostasis is achieved prior to discharge.   A limitation of the data set is that it is 
unknown whether the patient was actively bleeding on arrival to ENT, however, all patients had been 
referred for emergency ENT input. We define discharge time as the time from final haemostasis to 
discharge. Each interval was calculated by gathering data on the absolute date and time of each event. 
Additionally, we will discuss rates of 30-day recurrent presentation (RP), defined as representations to 
hospital with epistaxis in the 30 days following the point of initial presentation. The objective of the 
statistical analysis was primarily to assess compliance with national consensus recommendations that 
formed our audit standards, and thereafter, to identify which patient factors and treatments (both prior to 
ENT and at the first ENT review) were associated with variation in outcome in terms of HT and RP.   
 
During the exploratory analysis, it was determined that HT was positively skewed and multimodal as there 
were two modes (i.e. peaks in the data). To compensate for the skewed distribution of the data, a log 
transformation was applied to HT.  Plots of HT are presented in log hours, but summary statistics are given 
in hours unless otherwise stated.  Although this provides visual representation to observed differences in 
treatment, it was unable to account for all potential confounding factors. A future study will conduct 
inferential analysis of the dataset via regression modelling, which will provide us with the tools to account 
for associations with multiple treatments and potential confounders.  
 
RESULTS  
   
The audit was conducted simultaneously in 113 hospitals from all regions of the UK serving a combined 
population at risk of 51 million people. 1826 cases were uploaded, of which 1358 were gathered 
prospectively, in total this represented 94% of all cases presenting to involved units that met inclusion 
criteria.  The median number of cases uploaded per unit was 14 (range 1-50).  Scrutiny of the dataset 
discovered 89 cases did not meet inclusion criteria and 157 cases did not report a HT and so were excluded 
from analysis.  Follow-up data was available for 1469 patients who could be matched with the audit data. 
Once excluding those not within the audit period and undertaking relevant data manipulation, we were 
left with 1152 patients. 30 patients had a HT of 0 suggesting ED treatment had successfully treated 
patients without ENT input.  Consequently, these patients were excluded leaving 1122 patients for 
analysis. The RP rate for these patients was 24.1%, compared with 13.9% for the larger group of 1122 
patients. Whilst the difference appears substantial, any conclusions drawn from only 30 patients should be 
treated cautiously. 
 
The median age was 73 years, the inter-quartile range (IQR) was 62-82 years and the range was 16 - 100 
years. with larger proportion of males versus females (56% vs 44%). The median LOS was 29.5 hours with 
IQR of 11.1-51.0 hours. This was divided into time to first ENT review (median 2.4, IQR 1.1-4.6), HT (median 
18.5, IQR 1.0-33.7) and discharge time (median 3.5, IQR 1.1-17.0).  25% of patients achieved final 
haemostasis within 1 hour of their ENT review.  Approximately 62% of cases were successfully treated by 
ENT within 24 hours of their first review.  The longest period for any case to achieve achieved final 
haemostasis was just over 6 days, with less than 1.5% of patients requiring treatment for more than 4 days 
(fig.1). The 30-day RP rate across the data set was 13.9%.  30-day serious adverse event analysis revealed 
specific events occurred at the following rates: all-cause mortality 3.4%; myocardial infarction 0.7%; 
cerebrovascular accident 0.5%; pulmonary embolism 0.2% and deep vein thrombosis 0.1%. 
 
fig. 1 – Patients achieving final haemostasis over time 
 
Initial Assessment: 
The Modified Early Warning Score (MEWS)(11) is a nationally recognised and validated method of patient 
assessment which combines physiological parameters and observations to rapidly grade a patient’s degree 
of illness.  MEWS was reported in 841 cases (75.0%).  Higher MEWS was associated with increased HT; this 
was evident in the 7.0% of patients with MEWS ≥ 4 vs MEWS < 4 (23.0 (IQR 12.7-36.0) vs 18.8 (IQR 1.1-
34.3)) which represented 7.0% of cases.  Patients with MEWS ≥ 4 were associated with a lower risk of RP 
compared to patients with MEWS < 4 (0.0% vs 14.6%), however, numbers for analysis were small (fig. 2.). 
 
fig. 2 – Haemostasis time by MEWS score 
 
The World Health Organisation (WHO) bleeding classification(12) is an internationally accepted method for 
categorising the severity of bleeding, initially developed in the context of oncology patients. There are 
various condition-specific sub-classifications including a three-grade score for the severity of epistaxis. This 
score is calculated according to the total duration of bleeding in the previous 24 hours (<30mins = grade I, 
>30mins II) plus the requirement for transfusion of red blood cells (grade III).  This is the only accepted 
classification for the severity and duration of epistaxis.  Within our dataset a WHO grade could be 
calculated in 1115 cases (99.4%), with 12.8% of cases classified grade I, 82.7% grade II and 4.5% grade III. 
Patients with a higher WHO grade had longer median HT, with the largest difference in median between 
grade I and III (1.0 (IQR 0.3-20.7) vs 42.6 (IQR 19.1-75.8)) (fig. 3). 25.0% of patients with grade III bleeds 
represented within 30-days, compared with 13.5% of grade II and 12.3% of grade I. 
 
fig. 3 – Haemostasis time by WHO bleeding grade 
 
The initial ENT assessment was predominantly performed by junior-grade doctors (n=950, 86.6%) followed 
by middle-grade doctors (n=107, 9.2%), nurse practitioners (n=38, 3.5%) and consultants (n=8, 0.7%) (tab. 
1).  For each WHO bleed grade, specialist nurses have the lowest median HT. However, the number of 
patients seen by specialist nurses and consultants was very small. Therefore, it is unlikely that the 
estimates for median HT are representative or reliable. Neither a nurse specialist nor consultant saw a 
patient with a MEWS > 4, 95% of these patients were attended to by junior grade doctors. Although the 
evidence suggested the nurses tended to have a lower HT, the 30-day recurrent rates were notably higher. 
RP for patients seen by nurse practitioners was 21.6%, compared to junior-grades with 13.6%, middle-
grades with 14.6% and consultants with 14.3%. 
 
Practitioner 
seniority 
WHO I WHO II WHO III 
Median (IQR) n Median (IQR) n Median (IQR) n 
Consultant 0.3 1 5.5 (1.4 - 25.0) 7 - 0 
Junior grade 1.0 (0.3-20.3) 122 19.2 (2.0 - 34.7) 781 42.6 (22.4, 72.1) 42 
Middle grade 3.5 (1.5 - 20.3) 9 23.8 (1.4 - 37.2) 84 75.9 (31.6 - 81.2) 6 
Nurse specialist 0.7 (0.5 - 5.3) 6 1.0 (0.4 - 26.7) 31 8.0 1 
Tab.1 Median homeostasis time in hours (IQR) grouped by severity of bleeding and seniority of practitioner 
 
Regarding co-morbidities, a past medical history of hypertension (formally diagnosed through sustained 
ambulatory blood pressure monitoring) was reported in 55% of cases.  The median HT in these patients 
was 20.3 (IQR 1.5-36.0) compared with 15.2 in those without a history of hypertension (IQR 0.6-29.7) and 
RP rates were 14.0% vs 13.8% respectively.  26.0% of cases reported previous epistaxis presentations with 
in the preceding year.  Median HT was 21.3 (IQR 1.3-37.2) in patients declaring previous bleeds vs 17.7 
(IQR 0.9-31.3) who did not, RP was nearly double in these patients (20.2% vs 12.1%). Patients who 
subsequently represented within 30-days of discharge had a shorter median HT during their initial 
treatment (16.5 vs 18.6). 156 (14.4%) individuals had a past medical history of diabetes mellitus and 333 
(30.4%) had ischaemic heart disease. However, neither condition demonstrated a potential association 
with varying haemostasis time. The RP was greater in those with a history of diabetes mellitus (21.4% vs 
12.3%) and also greater in those with a history of ischaemic heart disease (14.9% vs 13.0%).  
 
A history of previous epistaxis presentation within the preceding year was reported in 26.0% of cases. 
Patients declaring previous bleeds had a longer median HT of 21.3 (IQR 1.3-37.2) compared to 17.7 (IQR 
0.9-31.3) for those who did not. The RP was also greater in these patients at 20.2% compared to 12.1%. In 
the subset of patients who subsequently represented with a second episode of epistaxis within 30-days of 
their primary presentation, the subsequent median HT was found to be longer (16.5 vs 18.6 hours).  
 
Data were collected regarding time of presentation to investigate any associations with out of hours 
treatment. Working hours were defined as 0800-1700 and out of hours were defined as 1700-0800, seven 
days a week.  There was no potential association between median HT and day of presentation or whether 
presentation was in-hours or out-of-hours.  Anterior rhinoscopy was performed at initial assessment in 
71.9% of cases.  Analysis of the outcome of these patients demonstrated no difference in median HT or RP 
of 13.6% when compared to patients who did not undergo this examination.  A full blood count (FBC) was 
performed in 84.0% of cases and a coagulation screen in 65.4%.    Patients who underwent these 
investigations had longer median HT when compared to patients who did not have the specific test (FBC - 
20.4 vs 0.8, coagulation screen - 20.5 vs 9.4) 
 
Cautery: 
Cautery was performed in 365 cases (32.5%) during the initial ENT review, with a topical vasoconstrictor 
used in 116 (31.8%) of cases. Silver nitrate was utilised in most cases (97.5%) with only 9 patients treated 
with bipolar cautery.  Median HT was 0.5 hours in the silver nitrate group (IQR = 0.3-2.9), however, low 
numbers in the bipolar group made meaningful comparison impossible. Patients who received cautery at 
their first ENT review had a substantially shorter median HT (fig. 4). 30-day outcome data demonstrated a 
higher RP in patients who underwent cautery during their first ENT review (17.3% vs 12.3%).  Rigid 
endoscopy or microscopy was utilised during cautery at the initial ENT review in 17 (4.7%) cases.  
 
fig. 4 – Haemostasis time by cautery status 
 
Intranasal devices and haemostatic agents:  
In total, 517 (46.1%) patients were packed prior to ENT review. Packing prior to ENT review was associated 
with a longer median haemostasis time, however, if this pre-ENT pack was removed during initial ENT 
assessment then haemostasis time reduced substantially.  In fact, there was minimal difference in 
haemostasis time between those who were never packed compared with those who had their pre-ENT 
pack removed at initial ENT assessment with no subsequent replacement packing (fig. 5).   Patients packed 
prior to ENT review and patients packed at initial ENT review had a lower RP when compared with patients 
who were never packed (packed prior to ENT = 12.8% vs 14.9%, packed by ENT = 9.4% vs. 15.5%). 49 (6.4%) 
of patients who were packed received antibiotics upon discharge.  
 
fig. 5 – Haemostasis time by packing status 
 
The type of packing used was classified into one of five categories: inflatable (e.g. Rapid rhino), non-
dissolvable (e.g. Merocel), dissolvable (e.g. Nasopore), urinary catheter or haemostatic agent (e.g. 
Kaltostat).  75.4% of the patients packed prior to ENT received an inflatable packing (tab. 2). The median 
and inter quartile range for HT by pack type shows no difference between inflatable and non-dissolvable 
packs used prior to and by ENT. The number of patients packed with dissolvable, catheter and haemostatic 
packs was too small to gain useful insight.  
Consultation Pack type n (%) Median HT (IQR)  
Prior to first 
ENT review 
Inflatable 390 (74.7) 23.4 (150, 36.9) 14.1% 
Non dissolvable 128 (24.5) 23.3 (15.7, 37.9) 9.1% 
At first ENT 
review 
Inflatable 250 (83.3) 30.6 (20.0, 46.1) 8.2% 
Non-dissolvable 32 (10.7) 28.8 (19.5, 47.5) 6.9% 
Dissolvable  14(4.7) 11.3 (1.1, 29.4) 33.3% 
Catheter  4 (1.3) 41.3 (16.4, 75.5) 25.0% 
Tab. 2 Type of packs used and HT. Prior to the first ENT review there were also cases with dissolvable packs (n=2), catheter (n=1) and haemostatic agent (n=1). 
 
 
Of those packed with inflatable or non-dissolvable packs, the median number of packs placed per patient 
was 1 (IQR 1-2, range 1-6).  Patients requiring multiple packs were associated with an HT of 32.3 (IQR 20.3-
48.5) versus those with a single pack of 21.5 (IQR 12.5-34.5) and a RP of 9.7% vs 13.8%. Cautery was 
performed in 295 (38.8%) of packed patients following removal of their final pack. The RP was lower in this 
cautery group at 10.9% versus 12.9% amongst those packed but not cauterized following removal.   The 
median time to discharge from removal of final pack was 4.1 hours (IQR 1.5-16.0 hours).  
 
Haematological factors: 
In total 572 (51.0%) of the patients were on some form of antithrombotic medication (tab.3). Patients not 
on antithrombotic medication had a shorter median HT than those on anti-thrombotic medication (17.0 
(IQR 0.9-32.9) vs 19.3 (IQR 1.3-34.7)). Patients whose medication was stopped or reversed had a prolonged 
median HT compared to those who continued some form of treatment, this was the case across all 
medication types.  The cessation of antiplatelet agents was associated with lower RP as was the cessation 
or reversal of warfarin, however, this was not seen when DOACs were withheld.  The International 
Normalised Ratio (INR) of patients who had their warfarin reversed was higher than any other group of 
patients (tab. 4).   Median HT for patients taking warfarin was longer than patients taking DOACs. The 
median HT for patients on warfarin was 23.3 (IQR 4.9-39.0) vs oral anticoagulants 18.4 (IQR 1.6-29.0). The 
RP for all patients taking warfarin compared with oral anticoagulants was similar at 14.9% vs. 14.3%. 
Medicaton Status during 
admission 
n (%) Median HT (IQR) RP (%) 
Aspirin Unchanged 157 (14.0) 12.5 (0.4, 26.0) 11.7 
Stopped or  53 (4.7) 25.1 (17.5, 36.5) 6.5 
Altered 1 (0.1)    
Clopidogrel Unchanged 67 (6.0) 17.5 (0.4, 38.0) 14.5 
Stopped  33 (3.0) 25.2 (16.5, 38.3) 9.7 
Altered 2(0. 1)    
Heparins Unchanged 18 (1.6) 2.8 (0.5, 26.6) 18.8 
Stopped  6 (0.5) 44.1 (20.0, 50.6) 0.0 
Altered 2 (0.2)    
DOAC Unchanged  65 (5.8) 2.9 (0.5, 21.3) 12.3 
Stopped  74 (6.6) 23.4 (13.7, 37.9) 14.5 
Altered 3 (0.3) 20.8 (10.6, 35.1) 33.3 
Warfarin Unchanged  85 (7.1) 11.0 (0.4, 27.3) 24.3 
Stopped  105 (9.4) 28.8 (18.0, 42.4) 9.8 
Reversed 16 (1.4) 36.9 (23.8, 49.4) 0.0 
Altered 11 (1.0) 19.0 (0.9, 33.6) 12.5 
Tab. 3 Table showing modifications to antithrombotic medications against HT and RP  
 
 
Status during admission N (%) Median INR IQR 
Unchanged 67 (5.9) 2.6 (2.1, 2.9) 
Stopped 93 (8.3) 2.7 (2.4, 3.2) 
Reversed 15 (1.3) 3.9 (3.2, 6.6) 
Altered dose 10 (0.9) 3.0 (2.6, 3.6) 
Tab. 4 Warfarin status by INR 
 
Tranexamic acid (TXA) was administered to 92 (8.2%) of patients. The box plots suggest a marginally longer 
median HT for patients receiving TXA (fig. 6).  RP rates were also higher in patients who received TXA 
during their treatment (18.1% vs 13.5%). MEWS score data demonstrates patients receiving TXA tended to 
possess a higher degree of illness (tab. 5). Data suggests a slight increase in the time taken to achieve 
haemostasis in those receiving TXA via IV versus PO, and another slight increase between IV and Topically. 
However, these differences are relatively small. Furthermore, the amount of data available when split by 
mode of administration is small, and as such any results should be interpreted with caution. Transfusion of 
blood products was performed in 50 (4.5%) cases. Patients transfused had a median pre-transfusion 
haemoglobin of 91g/L (IQR 7-103) and a median MEWS of 1 with IQR (1,2). 
 
Fig. 6 – Haemostasis Time by tranexamic acid use and method of administration 
 
 
MEWS 
Tranexamic Acid  
N(%) 
No Yes 
0 216 (28.0) 16 (23.2) 
1 383 (36.7) 24 (34.8) 
2 140 (18.1) 10 (14.5) 
3 85 (11.0) 8 (11.6) 
4 32 (4.1) 7 (10.1) 
5 14 (1.8) 2 (2.9) 
6 1 (0.1) 2 (2.) 
7 1 (0.1) - 
Tab. 5. Patients given Tranexamic acid by MEWS score 
 
Surgery and Radiological Intervention: 
36 (3.2%) of included patients underwent surgery for epistaxis during the audit period. The median time 
between first ENT review and surgery was 24.7 and IQR (8.9, 54.2). Prior to surgery, these patients had a 
median number of pre-op non-dissolvable pack (inflatable + non-dissolvable) placements of 1 (IQR 1-2, 
range 0-6).  Patients undergoing surgery had a median MEWS of 1 and WHO grade of 2, this was the same 
as patients in the non-surgery group.  Data were available on the grade of principal surgeon grade for 34 of 
the 36 patients with consultants operating most commonly (52.9%) followed by registrars (44.1%).  
Operations performed were sphenopalatine artery ligation (n=19), sphenopalatine artery cautery (n=10), 
electrocautery of bleeding point (n=8), septoplasty (n=4), anterior ethmoid artery ligation (n=3) and 
antrostomy (n=1) with multiple operations being performed in some cases. The number of patients 
achieving final haemostasis at time of surgery was 17 (47.2%) and the RP rate of surgical patients was 
22.6%. 3 patients underwent radiological intervention with the low numbers preventing detailed analysis.  
All underwent intervention 2 days following first ENT review.  The maxillary artery was embolised in 2 
cases and isolated sphenopalatine artery embolisation was performed in 1 case.  
 
 
DISCUSSION & LIMITATIONS 
 
This large multicentre audit sought to benchmark current epistaxis management, enhance the evidence-
base and showcase trainee collaborative research as a strategy for large volume data collection.  The 
dataset successfully captured the vast majority of epistaxis presentations within involved units.  Data 
quality in general was high, however, it was limited by reliance on the detailed note taking of clinicians. It 
remains unclear whether missing data were due to deficiencies in management, note taking or data 
collection.  Incomplete data necessitated the exclusion of a number of cases from analysis, which had 
otherwise met the audit inclusion criteria.  This explorative analysis was able to identify potential 
associations between patient factors, treatment factors and outcomes.  Further inferential statistical 
analysis is planned, in a subsequent paper, to correct for confounding variables and modelling and identify 
optimal treatment strategies.  Without this additional analysis, suggested associations noted within the 
dataset thus far should be interpreted with caution. 
 
The large number of cases identified in this study highlights the considerable burden epistaxis places on 
our healthcare system, both at initial presentation and in the 13.9% of cases which represented to hospital 
attendance. The majority of cases were successfully treated within 24 hrs, suggesting a limited impact of 
disease on these individuals.  However significant event analysis revealed a 3.4% 30-day all-cause mortality 
rate within our dataset.  In context, the equivalent 30-day all-cause mortality rate for hip fracture in the UK 
is 7.1% ( http://www.nhfd.co.uk/nhfd/nhfd2015reportPR1.pdf / accessed 11/07/2017), a figure that has 
reduced from 10.9% over 8 years since the introduction of a program of ongoing national audit.  Whilst 
such figures should be interpreted with caution, and it is acknowledged that epistaxis may not be the 
condition directly leading to death in these cases, it highlights the level of morbidity held amongst the 
population of patients we treat.  
 
Assessment of auditable standards within the domain of initial assessment demonstrated high levels of 
adherence for the recording of key elements of the history, evidenced to effect outcome, within the 
medical notes.  Interestingly, our dataset supported a marked impact of some of these factors on outcome 
(duration of epistaxis, previous epistaxis, diabetes mellitus), whereas conditions such as ischaemic heart 
disease and known hypertension seemed to have minimal effect.  Initial ENT assessment was most 
frequently performed by junior doctors, however, reassuringly outcomes associated with these 
assessments were similar to those of their senior colleagues when cases were analysed by bleed severity. 
Anterior rhinoscopy was performed commonly and the majority of patients were investigated with a FBC 
and coagulation screen.  Cases where no blood tests were performed experienced a much shorter median 
HT.  This may suggest a lower complexity of presentation and, therefore, that investigations were ordered 
selectively on the basis of clinical concern, as the consensus statement recommends.  Audit data allowed 
us to calculate a WHO bleed severity in nearly all cases, however, the utility of this relatively crude grading 
system is questionable.  
 
At the time of initial ENT assessment, less than a third of patients had intranasal cautery performed and 
similarly only a third of patients had a topical vasoconstrictor applied. Both of these techniques have been 
recommended as first line treatment strategies in the consensus document. The use of electrocautery as 
first line was vanishingly rare despite its potentially superior outcomes(13).   Surprisingly, despite the 
dataset showing a lower median HT for those undergoing cautery, the recurrent bleed rate was nearly 50% 
higher, contrary to evidence previously published(14).  The majority of cautery was performed by junior 
doctors, though there was little to suggest that outcomes differed between clinician group. 
 
Nearly half of all patients referred to ENT were packed by other specialties prior to assessment, with the 
indication for such packs unclear from the dataset.  Packed patients were associated with longer median 
HT, but interestingly the small population who had their packs removed at initial assessment experienced a 
median HT that was the equivalent to the unpacked cases.  This supports the treatment strategy of pack 
removal at the point of initial ENT review to enable a more definitive assessment.  The lower RP seen in 
patients who were packed during their treatment suggests that such devices may not only be effective at 
achieving temporary haemostasis, but that they may also have a favourable effect on longer term 
outcomes.  Over three-quarters of patients receiving intranasal packs had an inflatable device used, as 
favoured in the consensus recommendations. The median HT was similar for inflatable and non-dissolvable 
packs, however, RP was lower for the latter group.  Following final pack removal, the median discharge 
time was found to be in line with the consensus recommendations, however, less than half of these 
patients underwent the recommended post-pack cautery.  Cautery following final pack removal was 
associated with a modestly lower RP. 
 
Over half of all patients were taking antithrombotic medication at initial presentation.  As per the 
consensus recommendations, the majority of patients continued to take antiplatelet medication 
throughout their treatment.  Those who stopped, had a lengthier HT which may suggest a greater burden 
of disease, although this group had a RP that was nearly half of that for patients continuing antiplatelet 
therapy. However, the number of representations was small, and a more detailed consideration of the risk 
and benefits of halting antiplatelet therapy for short periods would need to be explored.   
 
Warfarin and DOACs were the most common anticoagulants taken by epistaxis patients, with treatment 
stopped or reversed more commonly than maintained.  Contrary to consensus recommendations, the 
groups of patients who had warfarin therapy stopped or maintained both had similar median INR value, 
both within the most common therapeutic window of 2.0-3.0.  However, the dataset shows a much lower 
RP in patients who have warfarin stopped during their admission, suggesting such practice has a beneficial 
effect on epistaxis-specific outcome.  Patients who had warfarin reversed had a notably higher median INR, 
suggesting an element of patient selection in these cases. Epistaxis-specific outcomes between the 
warfarin and DOAC groups were similar, which reassures us of the relative safety of these novel agents 
despite current fears relating to the inability to reverse them. 
 
Data on TXA use showed longer median HT and higher RP in patients administered with the medication.  
However, the severity of illness differed notably in those receiving TXA and may represent a confounding 
factor.  Consequently, conclusions regarding the efficacy of TXA are unclear from this dataset.  Current 
practice appears to be in line with the consensus recommendation supporting the use of TXA in selected 
patients.   
 
Transfusion of blood products occurred more commonly than previously established in the literature(ref) 
with a median haemoglobin (Hb) at point of transfusion of 91 g/L.  This is above to 70-90 g/l target Hb 
recommended in the management of major trauma(15,16) and with 25% of transfused patients receiving 
blood products with a triggering Hb of >103 g/L it appears at present that the threshold to transfuse in 
some units may be too low. 
 
Surgery for epistaxis was performed infrequently, however, with a median time to intervention of just over 
24hrs and on average just one pre-operative pack insertion, escalation to theatre appeared expeditious.  
Despite this, there were still cases where patients received up to six pre-operative packing episodes prior 
to surgical intervention.  Small numbers limit the ability to draw conclusions regarding the efficacy of such 
procedures, however, given there was no difference between bleed severity and patient illness level 
between the surgical and non-surgical groups the RP rate of surgical patients of 22.6% appears high.  It is 
unclear from the dataset what the specific indications for surgical escalation were, especially in the context 
of a median pre-operative pack of just 1 and similar MEWS and WHO grade when comparing surgery and 
non-surgery groups.  The use of interventional radiology was very rare. 
 
CONCLUSIONS 
 
This large multicentre audit of epistaxis management further demonstrates the ability of trainee 
collaboratives to co-ordinate national projects involving the large-scale collection of data.  The dataset 
demonstrates management practices that variably adhere to the newly formed consensus 
recommendations.  Elements of this explorative analysis question our current understanding of previously 
well-established tenets of management for this common condition.  The observational nature of this study 
limits the strength of conclusions made, however, these findings highlight a number of areas where further 
research should be directed.   
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